Search our site
Hematology
International uniform response criteria for multiple myeloma
BGM Durie et al.
Leukemia (2006) 20: 1467-1473
Further study indicates only serum measurements needed for MM diagnosis or exclusion
Quantitation of serum free light chains in combination with protein electrophoresis and clinical information for
diagnosing multiple myeloma in a general hospital population.
Piehler, A. P., et al. Clin Chem, 2008. 54(11): p. 1823-30.
Publication of largest Light Chain Escape – Multiple Myeloma study to date
'Light-chain escape-multiple myeloma' - an escape phenomenon from plateau phase: report of the largest patient series using LC-monitoring.
A. Kühnemund et al. J Cancer Res Clin Oncol 2008, Sep 18.
doi 10.1007/s00432-008-0470-7
Read more:
www.freelite.co.uk/
BGM Durie et al.
Leukemia (2006) 20: 1467-1473
Further study indicates only serum measurements needed for MM diagnosis or exclusion
Quantitation of serum free light chains in combination with protein electrophoresis and clinical information for
diagnosing multiple myeloma in a general hospital population.
Piehler, A. P., et al. Clin Chem, 2008. 54(11): p. 1823-30.
Publication of largest Light Chain Escape – Multiple Myeloma study to date
'Light-chain escape-multiple myeloma' - an escape phenomenon from plateau phase: report of the largest patient series using LC-monitoring.
A. Kühnemund et al. J Cancer Res Clin Oncol 2008, Sep 18.
doi 10.1007/s00432-008-0470-7
Read more:
www.freelite.co.uk/
What is Freelite?
Freelite™ is a major breakthrough for the detection and monitoring of Multiple Myeloma (MM) and other B-cell dyscrasia.
There is now significant clinical evidence indicating the benefit of serum free light chain assays in initial screening for
monoclonal gammopathies, identifying AL amyloidosis and Nonsecretory MM patients missed by conventional
electrophoretic methods, as a prognostic indicator for progression in myeloma, for risk stratification of MGUS patients
and rapid evaluation of treatment efficacy.
Freelite™ is a major breakthrough for the detection and monitoring of Multiple Myeloma (MM) and other B-cell dyscrasia.
There is now significant clinical evidence indicating the benefit of serum free light chain assays in initial screening for
monoclonal gammopathies, identifying AL amyloidosis and Nonsecretory MM patients missed by conventional
electrophoretic methods, as a prognostic indicator for progression in myeloma, for risk stratification of MGUS patients
and rapid evaluation of treatment efficacy.